9. The micronizing method of claim 7 wherein said compound is pulverized to a mean particle diameter of from 1 μm to about 25 μm with particles larger than 50 μm constituting a fraction of not more than 2% of a total number of particles.

10. The micronizing method of claim 8 wherein said compound is pulverized to a mean particle diameter of from 1 μm to about 25 μm with particles larger than 50 μm constituting a fraction of not more than 2% of a total number of particles.

A1

11. A chemical composition comprising a plurality of crystalline (E)-4-[2-[2-[N-acetyl-N-(4-methoxybenzenesulfonyl)amino]phenyl]ethenyl]pyridine 1-oxide particles with a mean particle diameter of from 1 μm to about 25 μm with particles larger than 50 μm constituting a fraction of not more than 2% of a total number of particles.

12. A pharmaceutical composition comprising a therapeutically effective amount of the plurality of crystalline (E)-4-[2-[2-[N-acetyl-N-(4-methoxybenzenesulfonyl)amino]phenyl]ethenyl]pyridine 1-oxide particles of claim 11 as an active ingredient.

13. An anticancer drug comprising a therapeutically effective amount of the plurality of crystalline (E)-4-[2-[2-[N-acetyl-N-(4-methoxybenzenesulfonyl)amino]phenyl]ethenyl]pyridine 1-oxide particles of claim 11 as an active ingredient.

REMARKS

The present amendment has been made to delete multiple dependencies and otherwise bring the claims into conformance with United States patent practice, and to limit the fees. Early and favorable action is respectfully requested.